Drugs / Homotaurine
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT06431113 | Jan 2024 → Mar 2025 | glaucoma | Fondazione IRCCS Policlinico San Matteo di Pavia | Completed | No outcome recorded |
| Phase 3 | NCT00314912 | May 2006 → ? | Alzheimer disease | Bellus Health Inc. - a GSK company | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05022186 | Apr 2021 → Dec 2022 | cognitive impairment with or without cerebellar ataxia | Aristotle University Of Thessaloniki | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Homotaurine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06431113 ↗ |
| Known as | 3APS | “The purpose of this Phase III open-label extension study is to evaluate the long-term safety of Tramiprosate (3APS) in patients with mild to moderate Alzheimer's disease.” NCT00314912 ↗ |
| Known as | Tramiprosate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00314912 ↗ |